Respiratory function in Parkinson's disease.
This article reviews the spectrum of respiratory dysfunction in Parkinson's disease (PD). It includes the primary effects of PD on the ventilation, response to medications, and pulmonary complications of antiparkinson therapy. Primary pulmonary abnormalities include a restrictive change mainly secondary to chest wall rigidity and upper airway obstruction; both are responsive to dopaminergic modulation. Respiratory dyskinesia, a side effect of levodopa therapy, may produce both restrictive and dyskinetic ventilation. Therapy with ergot derivatives may result in pleuropulmonary fibrosis. Lastly, pulmonary infection as a consequence of disordered respiratory mechanics continues to contribute significantly to morbidity and mortality in PD.
Shill
H
H
Barrow Neurological Institute, Phoenix, Arizona, USA.
Stacy
M
M
D000978:Antiparkinson Agents / Q000009:adverse effects; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D012119:Respiration; D012120:Respiration Disorders / Q000139:chemically induced; D015656:Respiratory Mechanics
D000978:Antiparkinson Agents; D007980:Levodopa